DexCom, Inc.

NASDAQ:DXCM

Medical - Devices

Healthcare
$82.52 +1.27%

+$0.90 today

Market cap
$30.78B
Beta
1.44
P/E (TTM)
29.9
EPS (TTM)
$2.42
52W Low $54.11High $89.98

Volume 4.25M

Average 5.43M

DXCM Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

DexCom, Inc.NASDAQ: DXCM

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures declines year over year

Q2 FY2026 capital expenditures of $84.7M (cash outflow) fell 10.0% year over year, ahead of the -17.6% change in trailing-twelve-month capital expenditures. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at -0.1% a year.

Context

  • Capital expenditures amounted to 7.8% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -10.0% holds above the trailing-twelve-month pace of -17.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$84.7M+10.6% QoQ
Last fiscal yearDec 2025
-$363.5M+1.3% YoY
LTMJun 2026
-$343.7M-17.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.0%——
1 year+1.3%——
3-year CAGR-0.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(363.5M) USD
Year-over-year change
-1.3%

Capital Expenditures vs competitors

How DXCM compares with its peers on the latest reported figures

  • DXCM's LTM Jun 2026 capital expenditures of $343.7M is the largest of the 7 companies compared; the peer median is $14.8M.
  • Its year-over-year change of -17.6% is the 5th highest of 6, against a peer median of +31.1%.
  • Capital expenditures amounts to 6.9% of revenue for DXCM, versus a peer median of 4.0%.
DXCM Competitors Peer median
Capital Expenditures for DXCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$343.7M -17.6%-0.1%6.9%
PODDInsulet CorporationLTM Jun 2026$212.9M +80.1%+6.8%7.0%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$211M —+10.1%6.5%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$23.25M +31.1%-16.4%2.3%
BBNXBeta Bionics, Inc.LTM Mar 2026$6.34M +90.9%+90.0%5.8%
SENSSenseonics Holdings, Inc.LTM Mar 2026$793K -66.4%+52.9%1.9%
DRIODarioHealth Corp.LTM Mar 2026$142K +25.7%-37.2%0.7%
MMEDVMiniMed Group, Inc.—— ———
Peer median (excluding DXCM) $14.8M+31.1%+8.5%4.0%

Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income154.7M341.2M541.5M576.2M836.3M
Depreciation & Amortization102M155.9M186M217.7M251.8M
Deferred Income Tax(4.9M)(21.6M)(55M)(43.8M)182.2M
Stock-Based Compensation113.4M126.5M150.8M170.4M159.6M
Change in Working Capital(132M)27.7M3.2M108.8M103.4M
Accounts Receivables(75.5M)(199.9M)(260.1M)(35M)(201.9M)
Inventory(112.2M)49.3M(252.6M)12.4M(63.7M)
Accounts Payables58M295.1M466.5M211.7M347M
Other Working Capital(2.3M)(116.8M)49.4M(80.3M)22M
Other Non-Cash Items209.3M39.8M(78M)(39.8M)(92.6M)
Operating Cash Flow442.5M669.5M748.5M989.5M1.44B
Capital Expenditures(389.2M)(364.8M)(236.6M)(358.8M)(363.5M)
Acquisitions (Net)(30.2M)(3.9M)000
Purchases of Investments(2.47B)(2.27B)(3.2B)(2.66B)(1.27B)
Sales of Investments2.67B2.13B2.95B2.82B2.16B
Other Investing Activities10.1M(14.3M)(17.6M)(15.5M)600K
Investing Cash Flow(216.1M)(521.5M)(507.2M)(207.5M)536M
Debt Repayment00443.3M0(1.21B)
Common Stock Issued20.3M22.5M26.6M28.2M28.1M
Common Stock Repurchased0(557.7M)(688.7M)(750M)(500M)
Dividends Paid00000
Other Financing Activities(9.9M)(17.3M)(99.8M)(13M)(7M)
Financing Cash Flow10.4M(552.5M)(318.6M)(734.8M)(1.69B)
Effect of Forex Changes(1.4M)(5.8M)1.5M(7.4M)21.5M
Net Change in Cash235.4M(410.3M)(75.8M)39.8M311.8M
Free Cash Flow53.3M304.7M511.9M630.7M1.08B

DexCom, Inc.

NASDAQ:DXCM

Intrinsic Alpha fair value

Locked

Current Price

$82.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.